>
How Money Metals Exchange is Challenging the System: A Call for Sound Money and Grassroots Advocacy
Does wireless tech cause cancer or is it just another "coincidence"...
Federal Reserve Refuses to Provide Records of Foreign Gold Holdings
Biden Sending Aid, Guns, and Money Won't Fix Haiti
Scientists Close To Controlling All Genetic Material On Earth
Doodle to reality: World's 1st nuclear fusion-powered electric propulsion drive
Phase-change concrete melts snow and ice without salt or shovels
You Won't Want To Miss THIS During The Total Solar Eclipse (3D Eclipse Timeline And Viewing Tips
China Room Temperature Superconductor Researcher Had Experiments to Refute Critics
5 video games we wanna smell, now that it's kinda possible with GameScent
Unpowered cargo gliders on tow ropes promise 65% cheaper air freight
Wyoming A Finalist For Factory To Build Portable Micro-Nuclear Plants
High-Speed Railway Progresses Towards 200-mph Dallas-Houston Line
27 Ft-tall 3D-printed Structure Built by New Robot | ICON's Multi-Story Robotic Construction Sys
In 2013, GlaxoSmithKline shutdown Sirtris (David Sinclair's company) about five years after spending $720 million to buy Sirtris.
David A. Sinclair, Ph.D., A.O. is a Professor in the Department of Genetics and co-Director of the Paul F. Glenn Center for the Biology of Aging at Harvard Medical School. Dr. Sinclair is co-founder of several biotechnology companies (Sirtris, Ovascience, Genocea, Cohbar, MetroBiotech, ArcBio, Liberty Biosecurity) and is on the boards of several others. He is also co-founder and co-chief editor of the journal Aging.
Life Biosciences was co-founded in 2017 by David A. Sinclair, PhD, AO, a professor in the Department of Genetics at Harvard Medical School, and Tristan Edwards, an investment professional who developed its innovative company structure.